SOHM（SHMN）株式概要SOHM, Inc.は、米国においてジェネリック医薬品およびプライベートブランド医薬品の開発、製造、販売、マーケティングを行っている。 詳細SHMN ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析高いレベルの非現金収入 過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( $3M )US市場と比較して、過去 3 か月間の株価の変動が非常に大きい+1 さらなるリスクすべてのリスクチェックを見るSHMN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.001125.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-1m1m2016201920222025202620282031Revenue US$1.3mEarnings US$190.6kAdvancedSet Fair ValueView all narrativesSOHM, Inc. 競合他社Adial PharmaceuticalsSymbol: NasdaqCM:ADILMarket cap: US$3.0mSonoma PharmaceuticalsSymbol: NasdaqCM:SNOAMarket cap: US$3.8mHepion PharmaceuticalsSymbol: OTCPK:HEPAMarket cap: US$2.6mSciSparcSymbol: NasdaqCM:SPRCMarket cap: US$2.4m価格と性能株価の高値、安値、推移の概要SOHM過去の株価現在の株価US$0.001152週高値US$0.002152週安値US$0.0007ベータ01ヶ月の変化0%3ヶ月変化8.37%1年変化57.14%3年間の変化57.14%5年間の変化-79.25%IPOからの変化-99.90%最新ニュースお知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.最新情報をもっと見るRecent updatesお知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.株主還元SHMNUS PharmaceuticalsUS 市場7D0%5.3%1.1%1Y57.1%44.3%28.7%株主還元を見る業界別リターン: SHMN過去 1 年間で44.3 % の収益を上げたUS Pharmaceuticals業界を上回りました。リターン対市場: SHMN過去 1 年間で28.7 % の収益を上げたUS市場を上回りました。価格変動Is SHMN's price volatile compared to industry and market?SHMN volatilitySHMN Average Weekly Movement19.8%Pharmaceuticals Industry Average Movement9.9%Market Average Movement7.2%10% most volatile stocks in US Market16.4%10% least volatile stocks in US Market3.1%安定した株価: SHMNの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: SHMNの 週次ボラティリティ は過去 1 年間で26%から20%に減少しましたが、依然としてUS株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2005n/aBaron Nightwww.sohm.comは、米国においてジェネリック医薬品およびプライベートブランド医薬品の開発、製造、販売、流通を行っている。同社は鎮痛剤、抗生物質、風邪薬、抗炎症薬、一般用医薬品、化粧品、栄養補助食品を提供している。また、製品の輸出も行っている。同社は、赤血球膜由来キャリアとゲノム編集技術を用いたゲノム編集分野で前進するため、Coastar Therapeutics社と共同研究契約を結んでいる。SOHM社は2005年に設立され、カリフォルニア州コロナに本社を置いている。もっと見るSOHM, Inc. 基礎のまとめSOHM の収益と売上を時価総額と比較するとどうか。SHMN 基礎統計学時価総額US$3.19m収益（TTM）-US$1.13m売上高(TTM)US$1.30m0.0xP/Sレシオ0.0xPER（株価収益率SHMN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計SHMN 損益計算書（TTM）収益US$1.30m売上原価US$962.58k売上総利益US$333.87kその他の費用US$1.47m収益-US$1.13m直近の収益報告Dec 31, 2012次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%SHMN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 16:42終値2026/05/22 00:00収益2012/12/31年間収益2012/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SOHM, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.
お知らせ • Jul 03Sohm, Inc. Appoints Ravi Kapoor as an Independent DirectorSOHM, Inc. announced the appointment of Mr. Ravi Kapoor as an Independent Director. With over three decades of extensive experience in corporate law, mergers and acquisitions (M&A), and financial management, Mr. Kapoor brings a wealth of expertise to the SOHM Board that will enhance the company's strategic vision and governance framework. Mr. Kapoor is the proprietor of Ravi Kapoor &Associates and a partner at Yan Advisory Services LLP and Amity Consultants LLP. He is a registered Insolvency Professional with the Insolvency &Bankruptcy Board of India, demonstrating his commitment to upholding the highest standards in corporate governance. He holds multiple qualifications, including M.Com, LLB, FCS, CAIIB, AMIMA, and PGDIPR, which have equipped him with a thorough understanding of the complexities of corporate operations. His professional journey spans various esteemed institutions and includes primary roles as a Company Secretary with notable companies. Throughout his career, Mr. Kapoor has served on the boards of several prestigious organizations, including Concord Biotech Limited and Sanghi Industries Limited (an Adani Group enterprise), where his contributions have been pivotal in driving growth and innovation.
お知らせ • Jun 13SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-Cell Immunotherapy from a Healthy Human DonorSOHM, Inc. announced that preliminary data from a 3rd party user resulted in ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model. The data was presented at the 2024 AACR conference in San Diego. This type of engineered T-Cell is called CAR-T (Chimeric Antigen Receptor T-Cell). This method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of virus and is able to engineer lung cancer cell killing CAR T-cells very efficiently. Dr. Aguilar, further stated that, CAR T-cell therapy is a form of cancer treatment that harnesses the power of a patient's own immune system to target and destroy cancer cells. Chimeric antigen receptor (CAR) T-cells are engineered patient immune cells that are designed to recognize and attack specific proteins on the surface of cancer cells. The importance of CAR T-cell therapy lies in its ability to provide targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options. The field of CAR T-cell therapy has seen significant growth and advancement in recent years, with several CAR T-cell therapies receiving approval from regulatory agencies for the treatment of certain types of blood cancers, such as leukemia and lymphoma. These approvals have paved the way for further research and development in the field, leading to the exploration of CAR T-cell therapy for other types of cancer. In addition to its potential to revolutionize cancer treatment, CAR T-cell therapy also holds promise for the treatment of other diseases, such as autoimmune disorders, neurological disease and infectious diseases. As researchers continue to refine and optimize CAR T-cell therapy, the field is expected to continue to grow and expand, offering new hope for patients battling cancer and other serious illnesses. On average, CAR T-cell therapy can cost anywhere from $373,000 to $475,000 per patient in the United States. This high cost is primarily due to the complex and personalized nature of CAR T-cell therapy, which involves the extraction, modification, and re-infusion of a patient's own immune cells. Overall, the market value for CAR T companies is expected to continue to grow as more research and development efforts are focused on advancing CAR T-cell therapy and expanding its application to a wider range of cancer types and other diseases. The high cost of CAR T-cell therapy presents challenges in terms of access and affordability, but ongoing efforts are being made to address these issues and make this innovative treatment more widely available to patients in need. More effective production methods via use of techniques like ABBIE genome editing will assist in bringing patient costs down and expanding use of the therapy to many more people affected by cancers.
お知らせ • May 24Sohm, Inc. Targets Revolutionary New Abbie Genome Editing Kits for Third Quarter, 2024SOHM, Inc. announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. This technology has the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The impact of ABBIE on genome editing cannot be overstated. By providing researchers with a powerful tool for targeted integration of foreign DNA, ABBIE has the potential to revolutionize the field of genetic engineering and open up new possibilities for the treatment of genetic diseases, the development of novel therapies, and the advancement of scientific research. The increased efficiency of safe genetic insertions with ABBIE will decrease time to obtain successful edits and the costs associated with lost time and additional reagents. The revolutionary new ABBIE system is due to be sold as off-the-shelf kits in third quarter. This has been possible due to committed, consistent and focused approach by lead scientists at UACI in Tucson, AZ. The company anticipates very high volume and revenues from its 1st generation ABBIE kits. There is an expected volume of thousands of kits sold, licensing and millions in revenue. The company has other types of kits and related products in development.
お知らせ • Nov 16SOHM, Inc. Launches Suite of 13 New SOHM Nutrients' Brand ChewablesSOHM, Inc. announced SOHM OTC Self-care launches a suite of 13 new SOHM Nutrients' Brand Chewables. SOHM OTC Self -care business unit is launching its suite of 13 new SohM Nutrients' Brand CheWables into the global vitamin gummies market. The global vitamins market is valued at $6.84 billion in 2022 and is expected to reach $18.76 billion by 2031 with a CAGR of 12.06% between 2023-2031. The suite of these 13 SOHM Nutrients’ Brand Chewables will be offering consumers these key features: Bone health, skin health, immune boost, mineral replenishment, and sleep aid; Convenience of individually wrapped single serving (pocket friendly); Chewables (no water required); Taste (mango, strawberry, pineapple, toffee). These SOHM Nutrients’ Brand Chewables also boast the same sought-after ingredients and labels as the leading vitamin gummies on Amazon.com: Turmeric, folic acid, multi-vitamins, multi-minerals; Nuts free; Gluten free; Gelatin free; Vegan; Soy free.
お知らせ • Aug 25SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical AdvisorSOHM, Inc. announced the appointment of Dr. Krishna Bhat, MD. Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor. Baron Night, SOHM president and CEO, said Dr. Bhathas a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which states: "In recognition of your commitment to excellence in the field of Cardiovascular Care through your leadership as an outstanding physician, researcher, and educator." Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
お知らせ • Aug 09SOHM, Inc. Appoints Dr. David Aguilar, Ph.D. as A Chief Operating OfficerSOHM, Inc. announce the appointment of Dr. David Aguliar, Ph.D. as Chief Operating Officer, effective immediately. Mr. Baron Night, CEO and President is please to share that, Dr. David Aguliar has a total of 22 years of experience in pharmaceutical industry coupled with multiple research and publications. He has an extensive background in significant CMC and Quality Assurance experience in preclinical and IND filings of allogeneic cell-based therapies. A deep understanding of regulatory and clinical pathways coupled with extensive scientific and technical background offers a unique perspective in developing assets from concept to clinic. His extensive academic and corporate experience in the field of pharmaceuticals, biopharmaceuticals and Gene Editing tools research etc. is a phenomenon. With his appointment as a COO, the company shall benefit tremendously for its vision and goals. Dr. Aguilar's Exceptional track record of following leadership will enhance the company's ability to achieve the goals and vision more quickly. His skills include but not limited to; Superior project management skills, Resourceful and analytical with exceptional communication skills, Understanding of all facets of business, Outstanding public speaking and interpersonal skills, Knowledge of AI tools and implementation in the current business infrastructure, Aptitude in problem-solving and decision-making, Understanding of analytics and performance metrics.
